NCT02806388 Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project
| NCT ID | NCT02806388 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Centre, Singapore |
| Condition | Solid Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,500 participants |
| Start Date | 2011-10 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,500 participants in total. It began in 2011-10 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to screen tumor molecular profile for better selection of anticancer treatment, in particular, allocation to clinical trials if available.
Eligibility Criteria
Inclusion Criteria: * Confirmed histological diagnosis of solid tumor * Suitable for systematic treatment and clinical trials * ECOG (Eastern cooperative oncology group) performance status \< 2 * Able to provide tumor tissue for molecular profiling * Able to understand and sign the informed consent form Exclusion Criteria: * None
Contact & Investigator
Daniel SW Tan
PRINCIPAL INVESTIGATOR
National Cancer Centre, Singapore
Frequently Asked Questions
Who can join the NCT02806388 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Solid Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02806388 currently recruiting?
Yes, NCT02806388 is actively recruiting participants. Contact the research team at daniel.tan.s.w@singhealth.com.sg for enrollment information.
Where is the NCT02806388 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT02806388 clinical trial?
NCT02806388 is sponsored by National Cancer Centre, Singapore. The principal investigator is Daniel SW Tan at National Cancer Centre, Singapore. The trial plans to enroll 5,500 participants.